MCID: HYP098
MIFTS: 50

Hypereosinophilic Syndrome malady

Categories: Genetic diseases, Rare diseases, Blood diseases

Aliases & Classifications for Hypereosinophilic Syndrome

About this section

Aliases & Descriptions for Hypereosinophilic Syndrome:

Name: Hypereosinophilic Syndrome 47 24 49 67
Hes 47 42
Disseminated Eosinophilic Collagen Disease 67
 
Hypereosinophilic Syndrome, Idiopathic 47
Idiopathic Hypereosinophilic Syndrome 67

Classifications:



Summaries for Hypereosinophilic Syndrome

About this section
Wikipedia:70 The hypereosinophilic syndrome (HES) is a disease characterized by a persistently elevated eosinophil... more...

MalaCards based summary: Hypereosinophilic Syndrome, also known as hes, is related to restrictive cardiomyopathy and churg-strauss syndrome, and has symptoms including hepatomegaly, pruritus and myalgia. An important gene associated with Hypereosinophilic Syndrome is PDGFRA (Platelet Derived Growth Factor Receptor Alpha), and among its related pathways are Cytoskeleton remodeling_Role of PDGFs in cell migration and Osteoblast Signaling. The drugs interferon alfa-2b and recombinant interferon beta-1a have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related mouse phenotypes are craniofacial and limbs/digits/tail.

Related Diseases for Hypereosinophilic Syndrome

About this section

Diseases in the Hypereosinophilic Syndrome family:

Secondary Hypereosinophilic Syndrome Primary Hypereosinophilic Syndrome

Diseases related to Hypereosinophilic Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 224)
idRelated DiseaseScoreTop Affiliating Genes
1restrictive cardiomyopathy29.7KIT, PDGFRA
2churg-strauss syndrome29.7IL5, RNASE3
3primary hypereosinophilic syndrome12.1
4hypereosinophilic syndrome, idiopathic, resistant to imatinib12.1
5lymphocytic hypereosinophilic syndrome12.0
6secondary hypereosinophilic syndrome12.0
7chronic eosinophilic leukemia10.7
8leukemia10.3
9keratoconjunctivitis10.2IL5, RNASE3
10toxic diffuse goiter10.2IL5, RNASE3
11chronic pulmonary heart disease10.2IL5, RNASE3
12fungal gastritis10.2IL5, RNASE3
13vibrio vulnificus infection10.2IL5, RNASE3
14thomsen and becker disease10.2IL5, RNASE3
15benign mammary dysplasia10.2IL5, RNASE3
16crustacean allergy10.2IL5, RNASE3
17orbital plasma cell granuloma10.2IL5, RNASE3
18granulomatous endometritis10.2IL5, RNASE3
19skin disease10.1IL5, RNASE3
20purpura fulminans10.1IL5, RNASE3
21acute gonococcal salpingitis10.1IL5, RNASE3
22apple allergy10.1IL5, RNASE3
23central nervous system origin vertigo10.1IL5, RNASE3
24lymphoma10.1
25pituitary hypoplasia10.1IL5, RNASE3
26peanut allergy10.1IL5, RNASE3
27dacryoadenitis10.1IL5, RNASE3
28gait apraxia10.1IL5, RNASE3
29autoimmune neuropathy10.1IL5, RNASE3
30paratyphoid fever10.1IL5, RNASE3
31buphthalmos10.1IL5, RNASE3
32relapsing epidemic typhus10.1KIT, PDGFRA
33eosinophilia10.1
34melanoacanthoma10.1IL5, RNASE3
35vagina leiomyosarcoma10.1KIT, PDGFRA
36vaginitis10.1IL5, RNASE3
37malignant biphasic mesothelioma10.1KIT, PDGFRA
38filamentary keratitis10.1KIT, PDGFRA
39geotrichosis10.1IL5, RNASE3
40lateral medullary syndrome10.1KIT, PDGFRA
41endocarditis10.1
42prostate small cell carcinoma10.1KIT, PDGFRA
43dentin caries10.1IL5, RNASE3
44pura syndrome10.1KIT, PDGFRA
45cerebritis10.1
46sarcoid meningitis10.1IL5, RNASE3
47mercaptolactate-cysteine disulfiduria10.1KIT, PDGFRA
48mastroiacovo de rosa satta syndrome10.0KIT, PDGFRA
49biliary tract disease10.0IL5, RNASE3
50corneal granular dystrophy10.0FIP1L1, KIT

Graphical network of the top 20 diseases related to Hypereosinophilic Syndrome:



Diseases related to hypereosinophilic syndrome

Symptoms for Hypereosinophilic Syndrome

About this section

UMLS symptoms related to Hypereosinophilic Syndrome:


hepatomegaly, pruritus, myalgia

Drugs & Therapeutics for Hypereosinophilic Syndrome

About this section

Drugs for Hypereosinophilic Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 168)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Methylprednisoloneapproved, vet_approvedPhase 4, Phase 3115383-43-26741
Synonyms:
(6S,8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one
(6a,11b)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6alpha,11beta)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6α,11β)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione
.DELTA.1-6.alpha.-Methylhydrocortisone
1-Dehydro-6alpha-methylhydrocortisone
1-dehydro-6alpha-Methylhydrocortisone
1-dehydro-6α-methylhydrocortisone
11-beta,17,21-Trihydroxy-6-alpha-methylpregna-1,4-diene-3,20-dione
11beta,17,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
11beta,17alpha,21-Trihydroxy-6alpha-methyl-1,4-pregnadiene-3,20-dione
11beta,17alpha,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
121673-01-6
4-08-00-03498 (Beilstein Handbook Reference)
46436_FLUKA
46436_RIEDEL
570-35-4
6 Methylprednisolone
6-Methylprednisolone
6-alpha-Methylprednisolone
6.alpha.-Methylprednisolone
6923-42-8
6alpha-Methyl-11beta,17alpha,21-trihydroxy-1,4-pregnadiene-3,20-dione
6alpha-Methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
6alpha-Methylprednisolone
6alpha-methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
83-43-2
AC1L1N7A
Artisone-Wyeth
Artisone-wyeth
BPBio1_000174
BRD-K35240538-001-03-1
BRN 2340300
BSPBio_000158
Besonia
Bio-0658
CHEBI:6888
CHEMBL650
CID6741
CPD000058330
D00407
D008775
DB00959
Depo-Medrol (acetate)
Dopomedrol
EINECS 201-476-4
Esametone
Firmacort
HMS1568H20
HMS2090B13
HSDB 3127
LMST02030178
LS-118498
Lemod
M0639_SIGMA
M1665
MEPRDL
MLS000028541
MLS001148159
MLS002207191
Medesone
Medixon
Medlone 21
 
Medrate
Medrol
Medrol (TN)
Medrol Adt Pak
Medrol Dosepak
Medrol adt pak
Medrol dosepak
Medrol, Solu-Medrol, Medrone, Methylprednisolone
Medrone
Mesopren
Metastab
Methyleneprednisolone
Methylprednisolon
Methylprednisolone
Methylprednisolone (JP15/USP/INN)
Methylprednisolone [USAN:INN:BAN:JAN]
Methylprednisolone, 6-alpha
Methylprednisolonum
Methylprednisolonum [INN-Latin]
Metilbetasone
Metilprednisolona
Metilprednisolona [INN-Spanish]
Metilprednisolone
Metilprednisolone [DCIT]
Metilprednisolone [Dcit]
Metipred
Metrisone
Metrocort
Metysolon
Moderin
MolPort-002-528-554
NCGC00022735-03
NCI60_001657
NSC-19987
NSC19987
Nirypan
Noretona
Predni N Tablinen
Prednol- L
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy-6alpha-methyl- (8CI)
Prestwick0_000279
Prestwick1_000279
Prestwick2_000279
Prestwick3_000279
Prestwick_622
Promacortine
Reactenol
S1733_Selleck
SAM002589984
SMR000058330
SPBio_002377
Sieropresol
Solomet
Summicort
Suprametil
U 7532
UNII-X4W7ZR7023
Urbason
Urbasone
Wyacort
ZINC03875560
delta(1)-6alpha-Methylhydrocortisone
delta(sup 1)-6-alpha-Methylhydrocortisone
methylprednisolone
methylprenisolone
2
Prednisoloneapproved, vet_approvedPhase 4, Phase 3115350-24-85755
Synonyms:
(11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione
.DELTA.1-Cortisol
.DELTA.1-Dehydrocortisol
.DELTA.1-Dehydrohydrocortisone
.DELTA.1-Hydrocortisone
.delta.-Cortef
.delta.-Stab
1,2-Dehydrohydrocortisone
1,4-Pregnadiene-11beta,17alpha,21-triol-3,20-dione
1,4-Pregnadiene-3,20-dione-11beta,17alpha,21-triol
1-Dehydrocortisol
1-Dehydrohydrocortisone
3,20-dioxo-11beta,17alpha,21-Trihydroxy-1,4-pregnadiene
46656_FLUKA
46656_RIEDEL
50-24-8
58201-11-9
8056-11-9
AC-1773
AC1L1L2E
Ak-Pred
Ak-Tate
Alphadrol
Articulose-50
BPBio1_000164
BRD-K98039984-001-03-0
BRN 1354103
BSPBio_000148
Bio-0666
Bubbli-Pred
C07369
CCRIS 980
CHEBI:8378
CHEMBL131
CID5755
CO-Hydeltra
CPD000718761
Co-Hydeltra
Codelcortone
Cordrol
Cortalone
Cotogesic
Cotolone
D00472
D011239
DB00860
Decaprednil
Decortin H
Delcortol
Delta F
Delta(1)-dehydrohydrocortisone
Delta-Cortef
Delta-Cortef (TN)
Delta-Ef-Cortelan
Delta-Stab
Delta-stab
Deltacortenol
Deltacortril
Deltacortril Enteric
Deltahydrocortisone
Deltasolone
Deltisilone
Depo-Medrol
Derpo PD
Derpo Pd
Dexa-Cortidelt Hostacortin H
Dexa-Cortidelt hostacortin H
Di Adreson F
Di-Adreson F
Di-Adreson-F
Di-adreson F
DiAdresonF
Dicortol
Donisolone
Dydeltrone
EINECS 200-021-7
Eazolin D
Econopred
Econopred Plus
Erbacort
Erbasona
Estilsona
Fernisolone
Fernisolone P
Fernisolone-P
Flamasone
HMS1568H10
HMS2090J05
HSDB 3385
Hostacortin H
Hydeltra
Hydeltra-Tba
Hydeltrasol
Hydeltrone
Hydrodeltalone
Hydrodeltisone
Hydroretrocortin
Hydroretrocortine
I-Pred
Inflamase Forte
Inflamase Mild
K 1557
Key-Pred
Klismacort
LMST02030179
LS-7669
Lentosone
Lite Pred
M-Predrol
 
MLS001304083
MLS002154250
MLS002207037
Medrol
Medrol Acetate
Metacortandralone
Methylprednisolone Acetate
Meti-Derm
Meticortelone
Metreton
MolPort-002-507-147
NCGC00179649-01
NSC 9120
NSC9120
NSC9900
Neo-Delta-Cortef
Nisolone
Nor-Pred T.B.A.
Ocu-Pred
Ocu-Pred Forte
Ophtho-Tate
Orapred
P0152_SIGMA
P0637
P6004_SIGMA
PRDL
PRED-G
Panafcortelone
Paracortol
Paracotol
Pediapred
Poly-Pred
Precortalon
Precortancyl
Precortilon
Precortisyl
Pred Forte
Pred Mild
Predair
Predair A
Predair Forte
Predalone 50
Predalone T.B.A.
Predate
Predate Tba
Predate-50
Predcor-25
Predcor-50
Predcor-Tba
Predisolone Sodium Phosphate
Predne-Dome
Prednelan
Predni-Dome
Prednicen
Predniliderm
Predniretard
Prednis
Prednisolona
Prednisolona [INN-Spanish]
Prednisolone (JP15/USP/INN)
Prednisolone (anhydrous)
Prednisolone Acetate
Prednisolone Sodium Phosphate
Prednisolone Tebutate
Prednisolone [INN:BAN:JAN]
Prednisolonum
Prednisolonum [INN-Latin]
Predonin
Predonine
Prelone
Prenolone
Prestwick0_000274
Prestwick1_000274
Prestwick2_000274
Prestwick3_000274
Prestwick_404
Rolisone
S1737_Selleck
SAM002264639
SMR000718761
SPBio_002367
Scherisolon
Solone
Steran
Sterane
Sterolone
Supercortisol
UNII-9PHQ9Y1OLM
Ulacort
Ultra Pred
Ultracorten H
Ultracortene H
Ultracortene-H
Ultracortene-Hydrogen
Ultracortene-hydrogen
ZINC03833821
component of Ataraxoid
component of K-Predne-Dome
delta(1)-Cortisol
delta(1)-Dehydrocortisol
delta(1)-Dehydrohydrocortisone
delta(1)-Hydrocortisone
delta(sup 1)-Cortisol
delta(sup 1)-Dehydrocortisol
delta(sup 1)-Dehydrohydrocortisone
delta(sup 1)-Hydrocortisone
delta-dehydrocortisol
delta-dehydrohydrocortisone
delta-hydrocortisone
prednisolone
3
Omalizumabapproved, investigationalPhase 4143242138-07-4
Synonyms:
242138-07-4
D05251
Ig gamma-1 chain C region
Omalizumab
 
Omalizumab (USAN/INN)
Omalizumab (genetical recombination)
Omalizumab (genetical recombination) (JAN)
Xolair
Xolair (TN)
4Anti-Asthmatic AgentsPhase 4, Phase 23369
5Adrenergic AgentsPhase 4, Phase 25140
6AlbuterolPhase 4, Phase 2408
7Adrenergic beta-AgonistsPhase 4, Phase 21640
8AntibodiesPhase 4, Phase 3, Phase 26045
9Adrenergic AgonistsPhase 4, Phase 22877
10Adrenergic beta-2 Receptor AgonistsPhase 4, Phase 2925
11Antibodies, MonoclonalPhase 4, Phase 3, Phase 23795
12Tocolytic AgentsPhase 4, Phase 2708
13AntiemeticsPhase 4, Phase 23888
14Respiratory System AgentsPhase 4, Phase 24818
15Neurotransmitter AgentsPhase 4, Phase 217734
16Bronchodilator AgentsPhase 4, Phase 22856
17ImmunoglobulinsPhase 4, Phase 3, Phase 26045
18Protective AgentsPhase 4, Phase 27190
19Anti-Allergic AgentsPhase 4, Phase 21490
20glucocorticoidsPhase 4, Phase 2, Phase 34920
21Hormone AntagonistsPhase 4, Phase 2, Phase 312778
22HormonesPhase 4, Phase 2, Phase 313979
23Gastrointestinal AgentsPhase 4, Phase 28109
24Autonomic AgentsPhase 4, Phase 29774
25Anti-Inflammatory AgentsPhase 4, Phase 2, Phase 310355
26Prednisolone phosphatePhase 4, Phase 31153
27Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 4, Phase 2, Phase 312767
28Antineoplastic Agents, HormonalPhase 4, Phase 2, Phase 35407
29Prednisolone hemisuccinatePhase 4, Phase 31153
30Methylprednisolone acetatePhase 4, Phase 31153
31Peripheral Nervous System AgentsPhase 4, Phase 3, Phase 2, Phase 122776
32Prednisolone acetatePhase 4, Phase 31153
33Neuroprotective AgentsPhase 41672
34Methylprednisolone HemisuccinatePhase 4, Phase 31153
35
EtoposideapprovedPhase 3, Phase 2, Phase 1123233419-42-036462
Synonyms:
(-)-Etoposide
121471-01-0
136598-18-0
201594-04-9
33419-42-0
35317-32-9
4'-Demethyl-epipodophyllotoxin 9-[4,6-O-(R)-ethylidene-beta-D-glucopyranoside
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside)
4'-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside)
4'-Demethylepipodophyllotoxin ethylidene-.beta.-D-glucoside
4'-O-Demethyl-1-O-(4,6-O-ethylidene-beta-D-glucopyranosyl)epipodophyllotoxin
4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside
4-Demethylepipodophyllotoxin-.beta.-D-ethylideneglucoside
51854-34-3
76576-58-4
9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
AB00438905
AC1L1FN8
AC1L1VT3
AC1L6246
AC1NR4OG
AC1O4WGG
AC1O7M1N
AC1Q47JJ
Ambap33419-42-0
BPBio1_000673
BRD-K37798499-001-02-5
BSPBio_000611
Bio1_000489
Bio1_000978
Bio1_001467
C01576
CCRIS 2392
CHEBI:4911
CHEBI:588795
CHEMBL44657
CID11758093
CID284997
CID3310
CID36462
CID5284558
CID6419930
CID6610299
CPD000112002
D00125
DB00773
DEMETHY-EPIPODOPHYLLOTOXIN,ETHYLIDENE GLUCOSIDE,
Demethyl Epipodophyllotoxin Ethylidine Glucoside
Demethyl-epiodophyllotoxin ethylidene glucoside
Demethylepipodophyllotoxin-beta-D-ethylideneglucoside
E0675
E1383_SIGMA
EINECS 251-509-1
EPE
EPEG
ETOP
Epipodophyllotoxin
Epipodophyllotoxin VP-16213
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-.beta.-D-glucopyranoside
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside (8CI)
Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-.beta.-D-glucopyranoside)
Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-beta-D-glucopyranoside)
Eposide
Eposin
 
Eposin, Vepesid, VP-16, Toposar, Etoposide
Etopol
Etopophos
Etopophos (phosphate salt)
Etoposid
Etoposide
Etoposide (JP15/USP/INN)
Etoposide (VP16)
Etoposide [USAN:INN:BAN:JAN]
Etoposido
Etoposido [INN-Spanish]
Etoposidum
Etoposidum [INN-Latin]
Etosid
HMS1569O13
HMS2052N05
HMS2089F14
HSDB 6517
I06-0248
KBioSS_002410
LS-1214
Lastet
MLS000049957
MLS001074951
MLS001424283
MLS002153463
MLS002207239
MLS002222184
MolPort-003-983-431
MolPort-004-905-001
MolPort-004-955-161
NCGC00025056-02
NChemBio.2007.10-comp19
NK 171
NSC 141540
NSC-141540
NSC141540
Prestwick0_000396
Prestwick1_000396
Prestwick2_000396
Prestwick3_000396
Prestwick_211
S1225_Selleck
SAM001246880
SMR000112002
SPBio_002532
ST056353
Toposar
UNII-6PLQ3CP4P3
VP 16
VP 16 (pharmaceutical)
VP 16-213
VP 16213
VP-16
VP-16-213
VePESID (TN)
VePesid
Vepesid
Vepesid J
Vepeside
ZINC03830818
ZINC03938684
Zuyeyidal
etoposide
nchembio.573-comp8
nchembio873-comp2
trans-Etoposide
36
DaunorubicinapprovedPhase 3, Phase 226420830-81-330323
Synonyms:
(+)-Daunomycin
(1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside
(7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
(7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
(8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione
(8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro--6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione
11006-54-5
11048-29-6
1407-15-4
149541-57-1
20830-81-3
23942-76-9
27576-81-4
28020-80-6
AB00514669
AC1L1JCP
AC1Q29OI
AI3-52942
Acetyladriamycin
Anthracyline
Antibiotics From Streptomyces Coeruleorubidus
Antibiotics from Streptomyces coeruleorubidus
BPBio1_000389
BRD-K43389675-003-02-7
BRN 1445583
BSPBio_000353
C01907
CCRIS 914
CHEBI:41977
CHEMBL178
CID30323
Cerubidin
Cerubidine
D07776
DAUNORUBICIN HCL
DB00694
DM1
Daunamycin
Daunarubicinum
Dauno-Rubidomycine
DaunoXome
DaunoXome (TN)
Daunoblastin
Daunoblastine
Daunomycin
 
Daunomycin Hydrochloride
Daunomycin, Hydrochloride
Daunorrubicina
Daunorubicin
Daunorubicin (INN)
Daunorubicin (liposomal)
Daunorubicin Hcl
Daunorubicin Hydrochloride
Daunorubicin [INN:BAN]
Daunorubicin, Hydrochloride
Daunorubicina
Daunorubicine
Daunorubicinum
Daunorubicinum [INN-Latin]
Daunoxome
EINECS 244-069-7
FI 6339
FI6339
HMS2089H04
HMS2091K06
HSDB 5095
LMPK13050002
LS-187381
LS-997
Leukaemomycin C
MolPort-002-533-961
NCGC00024246-05
NCGC00024246-06
NCGC00025173-01
NCI-C04693
NChemBio.2007.10-comp14
NSC 83142
NSC-82151
Ondena
Prestwick3_000487
RCRA waste no. U059
RP 13057
Rcra Waste No. U059
Rp 13057 Hydrochloride
Rubidomycin
Rubidomycin Hydrochloride
Rubomycin
Rubomycin C
Tocris-1467
UNII-ZS7284E0ZP
VS-103
daunorubicin
nchembio723-comp2
37
Cytarabineapproved, investigationalPhase 3, Phase 2, Phase 11093147-94-46253
Synonyms:
(beta-D-Arabinofuranosyl)cytosine
(beta-D-arabinofuranosyl)cytosine
1-.beta.-D-arabinofuranosyl-cytosine
1-Arabinofuranosylcytosine
1-beta -D-Arabinofaranosylcytosine
1-beta -D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone
1-beta -D-Arabinofuranosylcytosine
1-beta-D-Arabinofaranosylcytosine
1-beta-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone
1-beta-D-Arabinofuranosyl-Cytosine
1-beta-D-Arabinofuranosylcytosine
1-beta-D-Arabinofuranosylcytosine, Cytosine Arabinoside
1-beta-D-Arabinosyl-Cytosine
1-beta-D-Arabinosylcytosine
147-94-4
1beta -Arabinofuranasylcytosine
1beta -D-Arabinofuranosylcytosine
1beta -D-Arabinosylcytosine
1beta-Arabinofuranasylcytosine
1beta-D-Arabinofuranosylcytosine
1beta-D-Arabinosylcytosine
2(1H)-Pyrimidinone, 4-amino-1- -D-arabinofuranosyl- [CAS]
2(1H)-Pyrimidinone, 4-amino-1- -D-arabinofuranosyl
30399_FLUKA
4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin
4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin [Czech]
4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidine
4-Amino-1-b-D-arabinofuranosyl-2-(1H)-pyrimidinone
4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon
4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon [Czech]
4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone
4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
4-amino-1-beta-D-arabinofuranosylpyrimidin-2(1H)-one
69-74-9 (hydrochloride)
AC-1075
AC1L1M4F
AC1Q52OJ
AI3-52329
AR3
Alexan
Ara-C
Ara-C, Cytosine Arabinoside, Cytosar-U, Cytarabine
Ara-Cytidine
AraC
Arabinocytidine
Arabinofuranosyl Cytidine
Arabinofuranosylcytosine
Arabinosyl Cytosine
Arabinosylcytosine
Arabitin
Aracytidine
Aracytin
Aracytine
Arafcyt
BIDD:GT0371
BIDD:PXR0139
BTB15125
Beta-cytosine arabinoside
C02961
C1768_SIGMA
C2035
C9H13N3O5
CCRIS 913
CHEBI:28680
CHEMBL803
CHX 3311
CID6253
CPD000449317
CYTARABINE (SEE ALSO CYTARABINE HYDROCHLORIDE 69-74-9)
Citarabina
Citarabina [INN-Spanish]
Cytarabin
Cytarabina
Cytarabine
Cytarabine (JP15/USP/INN)
 
Cytarabine [USAN:INN:BAN:JAN]
Cytarabine liposome injection
Cytarabinoside
Cytarabinum
Cytarabinum [INN-Latin]
Cytarbel
Cytonal
Cytosar
Cytosar-U
Cytosine 1-beta-D-arabinofuranoside
Cytosine arabinofuranoside
Cytosine arabinose
Cytosine arabinoside
Cytosine arabinoside (VAN)
Cytosine beta-D-arabinofuranoside
Cytosine beta-D-arabinofuranoside hydrochloride
Cytosine beta-D-arabinoside
Cytosine, beta -D-arabinoside
Cytosine, beta-D-arabinoside
Cytosine-1-beta-D-arabinofuranoside
Cytosine-1-beta-D-arabinofuranoside hydrochloride
Cytosine-beta -D-arabinofuranoside
Cytosine-beta -arabinoside
Cytosine-beta-D-arabinofuranoside
Cytosine-beta-arabinoside
Cytosinearabinoside
D00168
DB00987
DepoCyte
Depocyt
Depocyt (TN)
Depocyt (liposomal)
Depocyte
EINECS 205-705-9
Erpalfa
FT-0082880
HMS2051K19
HMS2090A18
HSDB 3049
Intrathecal (injected into the spinal fluid) DepoCyt
Intrathecal cytarabine (also known as ara-C)
Iretin
LS-860
Lopac0_000316
MLS000758310
MLS001066340
MolPort-001-792-509
NCGC00093356-03
NCGC00093356-04
NCGC00093356-05
NCI-C04728
NSC 287459
NSC287459
S1648_Selleck
SAM001247012
SMR000449317
SR-01000075773-3
Spongocytidine
TL8001048
Tarabine
U 19920A
U-19,920
U-19920
UNII-04079A1RDZ
Udicil
ZINC03795098
beta -D-arabinosylcytosine
beta -arabinosylcytosine
beta -cytosine arabinoside
beta-Ara C
beta-Ara c
beta-Arabinosylcytosine
beta-Cytosine arabinoside
beta-D-Arabinosylcytosine
cytarabine
cytarabine liposome injection
cytosine-β-D-arabinofuranoside
38
LenograstimapprovedPhase 3, Phase 21202135968-09-1
Synonyms:
G-CSF (CHO cell derived)
Glycosylated recombinant G-CSF
Glycosylated recombinant granulocyte colony stimulating factor
 
Granulocyte colony stimulating factor 3 (CHO cell derived)
Granulocyte colony-stimulating factor lenograstim
Lenograstim (genetical recombination)
Lenograstim rDNA
39
AldesleukinapprovedPhase 339785898-30-2, 110942-02-4
Synonyms:
125-L-serine-2-133-interleukin 2 (human reduced)
 
Interleukin-2 aldesleukin
Interleukin-2(2-133),125-ser
Recombinant interleukin-2 human
40
Busulfanapproved, investigationalPhase 3, Phase 254055-98-12478
Synonyms:
1, 4-Dimethanesulfonoxybutane
1, 4-Dimethylsulfonoxybutane
1, {4-Bis[methanesulfonoxy]butane}
1,4-BUTANEDIOL DIMETHANESULFONATE
1,4-Bis(methanesulfonoxy)butane
1,4-Bis(methanesulfonyloxy)butane
1,4-Bis[methanesulfonoxy]butane
1,4-Butanedi yl dimethanesulfonate
1,4-Butanediol dimethanesulfonate
1,4-Butanediol dimethanesulphonate
1,4-Butanediol dimethylsulfonate
1,4-Butanediol, dimethanesulfonate
1,4-Butanediol, dimethanesulphonate
1,4-Butanediyl dimethanesulfonate
1,4-Di(methylsulfonoxy)butane
1,4-Dimesyloxybutane
1,4-Dimethane sulfonyl oxybutane
1,4-Dimethanesulfonoxybutane
1,4-Dimethanesulfonoxylbutane
1,4-Dimethanesulfonyloxybutane
1,4-Dimethanesulphonyloxybutane
1,4-Dimethylsulfonoxybutane
1,4-Dimethylsulfonyloxybutane
2041 C. B
2041 C. B.
2041 C.B
2041 C.B.
4-((Methylsulfonyl)oxy)butyl methanesulfonate
4-methylsulfonyloxybutyl methanesulfonate
55-98-1
AC-198
AC1L1DRQ
AC1Q4GRQ
AI3-25012
AKOS003614975
AN 33501
Ambap55-98-1
B1022
B2635_FLUKA
B2635_SIGMA
BRN 1791786
BSPBio_001920
BUSULFAN (1,4-BUTANEDIOL, DIMETHANESULFONATE)
Bisulfex
Busilvex
Busulfan
Busulfan (JP15/USP/INN)
Busulfan GlaxoSmithKline Brand
Busulfan Orphan Brand
Busulfan Wellcome
Busulfan Wellcome Brand
Busulfan [INN:JAN]
Busulfano
Busulfano [INN-Spanish]
Busulfanum
Busulfanum [INN-Latin]
Busulfex
Busulphan
Busulphane
Butanedioldimethanesulfonate
Buzulfan
C.B. 2041
C6H14O6S2
CB 2041
CCRIS 418
CHEBI:28901
CHEMBL820
CID2478
CPD000058613
Citosulfan
D002066
D00248
DB01008
DivK1c_000847
EINECS 200-250-2
FT-0083567
G.T. 41
GT 2041
GT 41
Glaxo Wellcome Brand of Busulfan
GlaxoSmithKline Brand of Busulfan
Glyzophrol
HMS1920I07
HMS2091O09
HMS502K09
 
HSDB 7605
I09-1371
IDI1_000847
InChI=1/C6H14O6S2/c1-13(7,8)11-5-3-4-6-12-14(2,9)10/h3-6H2,1-2H3
KBio1_000847
KBio2_000512
KBio2_003080
KBio2_005648
KBio3_001420
KBioGR_000698
KBioSS_000512
LS-1358
Leucosulfan
MLS001076666
MYLERAN (TN)
Mablin
Methanesulfonic
Methanesulfonic acid, tetram ethylene ester
Methanesulfonic acid, tetramethylene ester
Mielevcin
Mielosan
Mielucin
Milecitan
Mileran
Misulban
Mitosan
Mitostan
MolPort-001-783-406
Myeleukon
Myeloleukon
Myelosan
Myelosanum
Mylecytan
Myleran
Myleran Tablets
Myleran tablets
Myleran, Busulfex, Busulfan
Mylerlan
NCGC00090905-01
NCGC00090905-02
NCGC00090905-03
NCGC00090905-04
NCGC00090905-05
NCGC00090905-06
NCGC00090905-07
NCI-C01592
NCI60_041640
NCIMech_000192
NINDS_000847
NSC 750
NSC-750
NSC-750sulphabutin
NSC750
Orphan Brand of Busulfan
Prestwick_989
S1692_Selleck
SAM002554887
SMR000058613
SPBio_000253
SPECTRUM1500152
ST50825921
Spectrum2_000067
Spectrum3_000320
Spectrum4_000259
Spectrum5_000928
Spectrum_000092
Sulfabutin
Sulfabutin (VAN)
Sulphabutin
Tetramethylene Dimethane Sulfonate
Tetramethylene bis(methanesulfonate)
Tetramethylene bis[methanesulfonate]
Tetramethylene dimethane sulfonate
Tetramethylene {bis[methanesulfonate]}
Tetramethylenester Kyseliny Methansulfonove
Tetramethylenester kyseliny methansulfonove
Tetramethylenester kyseliny methansulfonove [Czech]
UNII-G1LN9045DK
WLN: WS1&O4OSW1
Wellcome Brand of Busulfan
Wellcome, Busulfan
X 149
acid, tetramethylene ester
alkylating agent: crosslinks guanine residues
busulfan
butane-1,4-diyl dimethanesulfonate
n-Butane-1,3-di(methylsulfonate)
41
AsparaginaseapprovedPhase 32229015-68-3
Synonyms:
Asparaginase (E. coli)
 
Elspar
L-asparagine amidohydrolase
Putative L-asparaginase precursor
42
ThioguanineapprovedPhase 382154-42-72723601
Synonyms:
154-42-7
2 Amino 6 Purinethiol
2-Amino 6MP
2-Amino 6mp
2-Amino-1,7-dihydro-6H-purin-6-thion
2-Amino-1,7-dihydro-6H-purin-6-thion [Czech]
2-Amino-1,7-dihydro-6H-purine-6-thione
2-Amino-6-MP
2-Amino-6-mercaptopurine
2-Amino-6-merkaptopurin
2-Amino-6-merkaptopurin [Czech]
2-Amino-6-purinethiol
2-Amino-9H-purine-6-thiol
2-Aminopurin-6-thiol
2-Aminopurin-6-thiol [Czech]
2-Aminopurine-6(1H)-thione
2-Aminopurine-6-thiol
2-Thioguanine
2-amino-1,9-Dihydropurine-6-thione
2-amino-1H-purine-6(7H)-thione
2-amino-3,7-dihydropurine-6-thione
2-aminopurine-6-thiol
5580-03-0
6 Thioguanine
6-Mercapto-2-aminopurine
6-Mercaptoguanine
6-TG
6-Thioguanine
6-Thioguanine (6-TG)
6-Thioguanine, Thioguanine
A4660_SIGMA
A4882_SIGMA
AC-11125
AC1MC379
AI3-26078
AKOS003389499
BSPBio_001994
BW 5071
C07648
C5H7N5S
CCRIS 8997
CHEBI:136864
CHEMBL727
CID2723601
D013866
D08603
DB00352
DX4
DivK1c_000428
EINECS 205-827-2
FT-0083572
Glaxo Wellcome Brand of Thioguanine
Glaxo Wellcome Brand of Tioguanine
GlaxoSmithKline Brand of Thioguanine
GlaxoSmithKline Brand of Tioguanine
Guanine, thio- (VAN)
HMS1921E09
HMS2092M11
HMS501F10
HSDB 2504
I14-1541
IDI1_000428
KBio1_000428
KBio2_000715
KBio2_002476
KBio2_003283
KBio2_005044
 
KBio2_005851
KBio2_007612
KBio3_001494
KBio3_002954
KBioGR_001452
KBioGR_002476
KBioSS_000715
KBioSS_002483
LS-888
LT00455187
Lanvis
Lanvis (TN)
MLS001333131
MLS001333132
MolPort-000-929-106
MolPort-001-813-204
MolPort-003-984-174
NCGC00094792-01
NCGC00094792-02
NCGC00094792-03
NCI60_041643
NCIOpen2_004153
NINDS_000428
NSC 752
NSC-752
NSC752
S1774_Selleck
SBB067147
SMP2_000326
SMR000857244
SPBio_000849
SPECTRUM1500573
ST50298831
Spectrum2_000695
Spectrum3_000577
Spectrum4_000926
Spectrum5_001455
Spectrum_000235
T0212
TG
THG
Tabloid
ThG
Thioguanin GSK
Thioguanin-GSK
ThioguaninGSK
Thioguanine
Thioguanine Hemihydrate
Thioguanine Monosodium Salt
Thioguanine Tabloid
Thioguanine [USAN:BAN]
Tioguanin
Tioguanina
Tioguanina Wellcome
Tioguanina [INN-Spanish]
Tioguanine
Tioguanine (INN)
Tioguanine GlaxoSmithKline Brand
Tioguaninum
Tioguaninum [INN-Latin]
UNII-FTK8U1GZNX
UNII-WIX31ZPX66
WLN: T56 BNM FYM INJ FUS HZ
Wellcome Brand of Thioguanine
Wellcome U3B
ZINC18085533
cMAP_000061
purine antimetabolite: antimetabolite: inhibits nucleic acid replication
thioguanine
43
Prednisoneapproved, vet_approvedPhase 2, Phase 3135953-03-25865
Synonyms:
(1S,2R,10S,11S,14R,15S)-14-hydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-diene-5,17-dione
(8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione
(8xi,9xi,14xi)-17,21-dihydroxypregna-1,4-diene-3,11,20-trione
.delta. E
.delta.(sup1)-Cortisone
.delta.-Cortelan
.delta.-Cortisone
.delta.-Cortone
.delta.-E
.delta.1-Cortisone
.delta.1-Dehydrocortisone
.delta.sone
1,2-Dehydrocortisone
1,4-Pregnadiene-17-alpha,21-diol-3,11,20-trione
1,4-Pregnadiene-17.alpha.,21-diol-3,11,20-trione
1,4-Pregnadiene-17alpha,21-diol-3,11,20-trione
1-Cortisone
1-Dehydrocortisone
17,21-Dihydroxypregna-1,4-diene-3,11,20-trione
17alpha,21-Dihydroxy-1,4-pregnadiene-3,11,20-trione
53-03-2
68-59-7
81552_FLUKA
AC-11112
AC1L1LB2
AC1Q29EZ
ACon0_000082
ACon1_000297
AI3-52939
Adasone
Ancortone
Apo-Prednisone
Apo-prednisone
BPBio1_000323
BRD-K85883481-001-04-2
BSPBio_000293
Betapar
Bicortone
Bio-0649
C07370
C21H26O5
CCRIS 2646
CHEBI:8382
CHEMBL635
CID5865
CPD001227202
Cartancyl
Colisone
Cortan
Cortancyl
Cortidelt
Cotone
DB00635
Dacorten
Dacortin
Decortancyl
Decortin
Decortisyl
Dehydrocortisone
Dekortin
Delcortin
Dellacort
Dellacort A
Delta Cortelan
Delta E
Delta E.
Delta-Cortelan
Delta-Dome
Delta-cortelan
Delta-cortisone
Delta-cortone
Delta-dome
Deltacortene
Deltacortisone
Deltacortone
Deltasone
Deltasone, Liquid Pred, Orasone, Adasone, Deltacortisone,Prednisone
Deltison
Deltisona
Deltisone
Deltra
Di-Adreson
Diadreson
EINECS 200-160-3
Econosone
Encorton
Encortone
Enkortolon
Enkorton
Fernisone
Fiasone
HMS1568O15
HMS2090J13
HSDB 3168
Hostacortin
In-Sone
Incocortyl
 
Juvason
Kortancyl
LMST02030180
LS-1325
Liquid Pred
Lisacort
Lodotra
MEGxm0_000443
MLS001061265
MLS001304073
MLS001335907
MLS001335908
MLS002154191
MLS002207083
Me-Korti
Metacortandracin
Meticorten
Meticorten (Veterinary)
Metrevet (Veterinary)
MolPort-001-740-041
NCGC00090766-01
NCGC00090766-02
NCGC00090766-03
NCI-C04897
NCI60_000008
NSC 10023
NSC10023
Nisona
Nizon
Novoprednisone
Nurison
Orasone
Origen Prednisone
P1276
P6254_SIGMA
PRD
Panafcort
Panasol
Paracort
Parmenison
Pehacort
Precort
Predeltin
Prednicen-M
Prednicorm
Prednicort
Prednicot
Prednidib
Prednilonga
Prednison
Prednisona
Prednisona [INN-Spanish]
Prednisone
Prednisone Intensol
Prednisone [INN:BAN]
Prednisonum
Prednisonum [INN-Latin]
Prednitone
Prednizon
Prednovister
Presone
Prestwick0_000077
Prestwick1_000077
Prestwick2_000077
Prestwick3_000077
Prestwick_405
Pronison
Pronisone
Rectodelt
Retrocortine
S1622_Selleck
SAM002264641
SK-Prednisone
SMR000718760
SMR001227202
SPBio_002214
Servisone
Sone
Sterapred
Supercortil
U 6020
UNII-VB0R961HZT
Ultracorten
Ultracortene
WLN: L E5 B666 CV OV AHTTT&J A1 E1 FV1Q FQ
Winpred
Wojtab
ZINC03875357
Zenadrid
Zenadrid (veterinary)
Zenadrid [veterinary]
delta cortelan
delta(sup 1)-Cortisone
delta(sup 1)-Dehydrocortisone
delta-1-Cortisone
delta-1-Dehydrocortisone
delta-Cortisone
delta-Cortone
44Pharmaceutical SolutionsPhase 3, Phase 27793
45Etoposide phosphatePhase 3, Phase 2, Phase 11232
46Immunosuppressive AgentsPhase 3, Phase 2, Phase 112770
47Immunoglobulin GPhase 3265
48Interleukin-2Phase 3553
49Topoisomerase InhibitorsPhase 3, Phase 1, Phase 24945
50Antiviral AgentsPhase 3, Phase 2, Phase 19732

Interventional clinical trials:

(show top 50)    (show all 84)
idNameStatusNCT IDPhase
1The Efficacy of Three Months-prednisolone Therapy for Chronic Eosinophilic PneumoniaCompletedNCT00632554Phase 4
2Steroid Treatment for Hypereosinophilic SyndromeRecruitingNCT01524536Phase 4
3Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma PatientsActive, not recruitingNCT02654145Phase 4
4Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late ComplicationsCompletedNCT00799461Phase 3
5Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid LeukemiaCompletedNCT00006363Phase 3
6Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma ControlCompletedNCT02281318Phase 3
7Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe AsthmaCompletedNCT01508936Phase 3
8A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic AsthmaCompletedNCT01287039Phase 3
9A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic AsthmaCompletedNCT01285323Phase 3
10A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic AsthmaCompletedNCT01270464Phase 3
11Compassionate Use of Mepolizumab in Subjects With Hypereosinophilic Syndrome (HES)RecruitingNCT00244686Phase 3
12Cessation Versus Continuation of Long-term Mepolizumab in Severe Eosinophilic Asthma PatientsRecruitingNCT02555371Phase 3
13Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic SyndromesActive, not recruitingNCT00369317Phase 3
14Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell TransplantActive, not recruitingNCT01305200Phase 3
15Effects of Mepolizumab Compared to Placebo on Airway Physiology in Patients With Eosinophilic Asthma: MEMORY StudyActive, not recruitingNCT02594332Phase 3
16Anti-Interleukin-5 (IL5) Monoclonal Antibody (MAb) in Prednisone-dependent Eosinophilic AsthmaEnrolling by invitationNCT02559791Phase 2, Phase 3
17Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)Not yet recruitingNCT02836496Phase 3
18Open-Label Extension Of Intravenous Mepolizumab In Patients With Hypereosinophilic SyndromeTerminatedNCT00097370Phase 3
19Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic AsthmaTerminatedNCT01290887Phase 3
20Study of STI571 in the Treatment of Patients With Idiopathic Hypereosinophilic Syndrome (HES) and Eosinophilic LeukemiasUnknown statusNCT00276926Phase 2
21Imatinib Mesylate (Gleevec) in the Treatment of Systemic SclerosisUnknown statusNCT00555581Phase 2
22Anti-Interleukin-5 Antibody to Treat Hypereosinophilic SyndromeCompletedNCT00017862Phase 2
23Intravenous Mepolizumab In Subjects With Hypereosinophilic Syndromes (HES)CompletedNCT00086658Phase 2
24Efficacy of Imatinib Mesylate in Hypereosinophilic SyndromesCompletedNCT00787384Phase 2
25Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic SyndromeCompletedNCT00266565Phase 1, Phase 2
262-Chlorodeoxyadenosine and Cytarabine in Patients With Idiopathic Hypereosinophilic Syndrome (HES)CompletedNCT00483067Phase 2
27A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Blood Related CancersCompletedNCT00109707Phase 1, Phase 2
28Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase EnzymesCompletedNCT00171912Phase 2
29Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare DiseasesCompletedNCT00154388Phase 2
30Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid LeukemiaCompletedNCT00096122Phase 1, Phase 2
31Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic CancerCompletedNCT00489203Phase 2
32Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell TransplantCompletedNCT00795769Phase 2
33Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid LeukemiaCompletedNCT00027872Phase 2
34Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid LeukemiaCompletedNCT00666588Phase 2
35Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT00407966Phase 2
363-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous LeukemiaCompletedNCT00381550Phase 2
37Lenalidomide in Treating Older Patients With Acute Myeloid LeukemiaCompletedNCT00352365Phase 2
38A Phase IIa Study of KHK4563CompletedNCT01412736Phase 2
39Efficacy, Safety, and Tolerability of SAR231893 (REGN668) in Patients With Persistent Moderate to Severe Eosinophilic AsthmaCompletedNCT01312961Phase 2
40Imatinib Mesylate to Treat Myeloproliferative Hypereosinophilic SyndromeRecruitingNCT00044304Phase 2
41Study to Evaluate Safety and Efficacy of Benralizumab in Subjects With Hypereosinophilic SyndromeRecruitingNCT02130882Phase 2
42A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological MalignanciesRecruitingNCT01384513Phase 2
43Eltrombopag Olamine in Improving Platelet Recovery in Older Patients With Acute Myeloid Leukemia Undergoing ChemotherapyRecruitingNCT02071901Phase 2
44Effect of OC000459 on Eosinophilic Airway Inflammation in Severe AsthmaRecruitingNCT02560610Phase 2
45Study to Evaluate Safety and Efficacy of Dexpramipexole (KNS-760704) in Subjects With Hypereosinophilic SyndromeActive, not recruitingNCT02101138Phase 2
46Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)Active, not recruitingNCT00255346Phase 2
47Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid LeukemiaActive, not recruitingNCT01627041Phase 2
48A Study to Determine the Safety and Efficacy of Imatinib Mesylate in Patients With Idiopathic Hypereosinophilic SyndromeTerminatedNCT00171860Phase 2
49Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaTerminatedNCT00096148Phase 2
50Cilengitide in Treating Patients With Acute Myeloid LeukemiaTerminatedNCT00089388Phase 2

Search NIH Clinical Center for Hypereosinophilic Syndrome

Inferred drug relations via UMLS67/NDF-RT45:

Genetic Tests for Hypereosinophilic Syndrome

About this section

Genetic tests related to Hypereosinophilic Syndrome:

id Genetic test Affiliating Genes
1 Hypereosinophilic Syndrome24 PDGFRA

Anatomical Context for Hypereosinophilic Syndrome

About this section

MalaCards organs/tissues related to Hypereosinophilic Syndrome:

35
Myeloid, Bone, Bone marrow, Heart, T cells, Liver, Skin

Animal Models for Hypereosinophilic Syndrome or affiliated genes

About this section

MGI Mouse Phenotypes related to Hypereosinophilic Syndrome:

40
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053829.3FGFR1, KIT, PDGFRA, PDGFRB
2MP:00053719.2FGFR1, KIT, PDGFRA, PDGFRB
3MP:00053818.8FGFR1, IL5, KIT, PDGFRA, PDGFRB
4MP:00053808.7FGFR1, IL5, KIT, PDGFRA, PDGFRB
5MP:00053898.0FGFR1, IL5, KIT, PDGFRA, PDGFRB

Publications for Hypereosinophilic Syndrome

About this section

Articles related to Hypereosinophilic Syndrome:

(show top 50)    (show all 635)
idTitleAuthorsYear
1
Hypereosinophilic syndrome. (28052805)
2017
2
Hypereosinophilic syndrome presenting with multiple organ infiltration and deep venous thrombosis: A case report and literature review. (27583887)
2016
3
Characterization of left atrial dysfunction in hypereosinophilic syndrome - Insights from the Motion analysis of the heart and great vessels by three-dimensional speckle tracking echocardiography in pathological cases (MAGYAR-Path) Study. (27118091)
2016
4
Idiopathic hypereosinophilic syndrome presenting with severe vasculitis successfully treated with imatinib. (27803915)
2016
5
Lymphocytic variant of hypereosinophilic syndrome mimicking peripheral T-cell lymphoma in a young woman. (27158718)
2016
6
Atypical Presentation of Intracardiac Floating Thrombi in Hypereosinophilic Syndrome Complicated With Stroke and Systemic Embolization: A Case Report. (26512591)
2015
7
CD30+ clonal T-cell lymphoid proliferation of the skin in a patient with hypereosinophilic syndrome. (25421540)
2015
8
Multiple cerebral infarctions in a patient with hypereosinophilic syndrome with LAPffler endocarditis: a case report. (25786753)
2015
9
An unusual case of idiopathic hypereosinophilic syndrome presenting with myopericarditis and a polypoid cardiac mass. (24769822)
2014
10
Eosinophilic cystitis and idiopathic hypereosinophilic syndrome in an eight-year-old girl. (25394455)
2014
11
Eosinophilic pericardial effusion in hypereosinophilic syndrome with restrictive cardiomyopathy. (25302417)
2014
12
Hypereosinophilic syndrome masquerading as a myocardial infarction causing decompensated heart failure. (24053402)
2013
13
Effect of cyclosporine on lymphocytic variant hypereosinophilic syndrome. (23669338)
2013
14
Long-term remission of lymphocytic hypereosinophilic syndrome with imatinib mesylate. (21919038)
2012
15
Spontaneous resolution of hypereosinophilic syndrome in an infant without treatment. (22510769)
2012
16
Imatinib mesylate may induce long-term clinical response in FIP1L1-PDGFRI+-negative hypereosinophilic syndrome. (21258876)
2012
17
Gadolinium-enhanced cardiovascular magnetic resonance for the detection and characterization of Loeffler endocarditis in patients with hypereosinophilic syndrome. (21963210)
2011
18
Hemophagocytic syndrome associated NK/T nasal type lymphoma presenting as hypereosinophilic syndrome: a case report and literature review. (21501869)
2011
19
A curious case of a 'burned-out' hypereosinophilic syndrome. (21429579)
2011
20
Medical therapy alone produces regression of combined aortic and mitral valve involvement in hypereosinophilic syndrome. (20956234)
2010
21
The proportion of CD3- CD4+ T-cell population remained unaffected after corticosteroids treatment for lymphocytic variant hypereosinophilic syndrome (L-HES). (20883323)
2010
22
Endomyocardial disease related to idiopathic hypereosinophilic syndrome: a cardiac magnetic resonance evaluation. (20396876)
2010
23
Wells Syndrome with Multiorgan Involvement Mimicking Hypereosinophilic Syndrome. (20652113)
2009
24
Successful treatment of refractory idiopathic hypereosinophilic syndrome with etoposide. (19142161)
2009
25
The hypereosinophilic syndromes: current concepts and treatments. (19243381)
2009
26
Treatment of FIP1L1/PDGFRA-negative hypereosinophilic syndrome with alemtuzumab, an anti-CD52 antibody. (19342084)
2009
27
Eosinophilic pleural effusion: a rare manifestation of hypereosinophilic syndrome. (20111739)
2009
28
Pregnancy in a patient with hypereosinophilic syndrome. (18597844)
2009
29
Hypereosinophilic syndrome and mepolizumab. (18584819)
2008
30
Clinical features of hypereosinophilic syndrome: FIP1L1-PDGFRA fusion gene-positive disease is a distinct clinical entity with myeloproliferative features and a poor response to corticosteroid. (17261495)
2007
31
A multicenter analysis of the FIP1L1-alphaPDGFR fusion gene in Japanese idiopathic hypereosinophilic syndrome: an aberrant splicing skipping the alphaPDGFR exon 12. (17701174)
2007
32
Erythrodermic cutaneous T cell lymphoma with hypereosinophilic syndrome: Treatment with interferon alfa and extracorporeal photopheresis. (17988344)
2007
33
Recurrent optic neuritis as the presenting manifestation of primary hypereosinophilic syndrome: a report of two cases. (15937435)
2005
34
Association of cutaneous necrotizing eosinophilic vasculitis and deep vein thrombosis in hypereosinophilic syndrome. (16103348)
2005
35
Idiopathic hypereosinophilic syndrome: toward a new molecular-targeted therapy and a new cytomorphological and molecular definition]. (15951264)
2005
36
Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome. (14984510)
2004
37
Rapid reversion of Loeffler's endocarditis by imatinib in early stage clonal hypereosinophilic syndrome. (15621768)
2004
38
Imatinib-mesylate for all patients with hypereosinophilic syndrome? (15158099)
2004
39
Eosinophilic myocarditis in a patient with idiopathic hypereosinophilic syndrome: insights into mechanisms of myocardial cell death. (15343520)
2004
40
Mitral valve repair in idiopathic hypereosinophilic syndrome. (15222304)
2004
41
Bone marrow necrosis with Charcot-Leyden crystals in a patient with idiopathic hypereosinophilic syndrome. (12969825)
2003
42
Unusual cardiac manifestation of hypereosinophilic syndrome. (12185226)
2002
43
The idiopathic hypereosinophilic syndrome. (11785603)
2001
44
Hypereosinophilic dermatosis: skin lesions as the only manifestation of the idiopathic hypereosinophilic syndrome? (10971369)
2000
45
Interferon-alpha in the idiopathic hypereosinophilic syndrome: consideration of five cases. (9829847)
1998
46
A case of idiopathic hypereosinophilic syndrome complicated with disseminated intravascular coagulation. (9723589)
1998
47
Allogeneic bone marrow transplantation for hypereosinophilic syndrome with advanced myelofibrosis. (9156253)
1997
48
Further evidence for the clonal nature of the idiopathic hypereosinophilic syndrome: complete haematological and cytogenetic remission induced by interferon-alpha in a case with a unique chromosomal abnormality. (8562393)
1996
49
Hypereosinophilic syndrome: cause of prosthetic valve obstruction. (7637374)
1995
50
Hypereosinophilic syndrome with evolution to myeloproliferative disorder: temporal relationship to loss of Y chromosome and c-N-ras activation. (2258361)
1990

Variations for Hypereosinophilic Syndrome

About this section

Expression for genes affiliated with Hypereosinophilic Syndrome

About this section
Search GEO for disease gene expression data for Hypereosinophilic Syndrome.

Pathways for genes affiliated with Hypereosinophilic Syndrome

About this section

Pathways related to Hypereosinophilic Syndrome according to GeneCards Suite gene sharing:

(show all 29)
idSuper pathwaysScoreTop Affiliating Genes
19.6PDGFRA, PDGFRB
29.6PDGFRA, PDGFRB
39.5KIT, PDGFRA
49.1FGFR1, PDGFRA, PDGFRB
5
Show member pathways
9.1FGFR1, PDGFRA, PDGFRB
69.1FGFR1, PDGFRA, PDGFRB
7
Show member pathways
9.1FGFR1, PDGFRA, PDGFRB
8
Show member pathways
9.1FGFR1, PDGFRA, PDGFRB
9
Show member pathways
9.1FGFR1, PDGFRA, PDGFRB
109.1FGFR1, PDGFRA, PDGFRB
11
Show member pathways
9.0KIT, PDGFRA, PDGFRB
12
Show member pathways
9.0KIT, PDGFRA, PDGFRB
13
Show member pathways
8.8FGFR1, KIT, PDGFRB
14
Show member pathways
8.6FGFR1, IL5, PDGFRA, PDGFRB
15
Show member pathways
8.4FGFR1, KIT, PDGFRA, PDGFRB
16
Show member pathways
8.4FGFR1, KIT, PDGFRA, PDGFRB
17
Show member pathways
8.4FGFR1, KIT, PDGFRA, PDGFRB
188.4FGFR1, KIT, PDGFRA, PDGFRB
19
Show member pathways
8.4FGFR1, KIT, PDGFRA, PDGFRB
20
Show member pathways
8.4FGFR1, KIT, PDGFRA, PDGFRB
218.4FGFR1, KIT, PDGFRA, PDGFRB
228.4FGFR1, KIT, PDGFRA, PDGFRB
238.4FGFR1, KIT, PDGFRA, PDGFRB
24
Show member pathways
8.4FGFR1, KIT, PDGFRA, PDGFRB
25
Show member pathways
8.0FGFR1, IL5, KIT, PDGFRA, PDGFRB
26
Show member pathways
8.0FGFR1, IL5, KIT, PDGFRA, PDGFRB
27
Show member pathways
8.0FGFR1, IL5, KIT, PDGFRA, PDGFRB
28
Show member pathways
8.0FGFR1, IL5, KIT, PDGFRA, PDGFRB
29
Show member pathways
8.0FGFR1, IL5, KIT, PDGFRA, PDGFRB

GO Terms for genes affiliated with Hypereosinophilic Syndrome

About this section

Cellular components related to Hypereosinophilic Syndrome according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1intrinsic component of plasma membraneGO:00312269.6PDGFRA, PDGFRB

Biological processes related to Hypereosinophilic Syndrome according to GeneCards Suite gene sharing:

(show all 22)
idNameGO IDScoreTop Affiliating Genes
1metanephric glomerular capillary formationGO:007227710.2PDGFRA, PDGFRB
2positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathwayGO:003809110.2PDGFRA, PDGFRB
3platelet-derived growth factor receptor signaling pathwayGO:004800810.1PDGFRA, PDGFRB
4cardiac myofibril assemblyGO:005500310.1PDGFRA, PDGFRB
5positive regulation of fibroblast proliferationGO:004814610.0PDGFRA, PDGFRB
6retina vasculature development in camera-type eyeGO:006129810.0PDGFRA, PDGFRB
7positive regulation of JAK-STAT cascadeGO:00464279.8IL5, KIT
8positive regulation of phosphatidylinositol 3-kinase activityGO:00435529.5KIT, PDGFRA, PDGFRB
9stem cell population maintenanceGO:00198279.5FGFR1, KIT
10cell chemotaxisGO:00603269.2KIT, PDGFRA, PDGFRB
11positive regulation of MAP kinase activityGO:00434069.2FGFR1, KIT, PDGFRB
12positive regulation of phospholipase C activityGO:00108639.1FGFR1, KIT, PDGFRA, PDGFRB
13phosphatidylinositol phosphorylationGO:00468549.0FGFR1, KIT, PDGFRA, PDGFRB
14regulation of phosphatidylinositol 3-kinase signalingGO:00140669.0FGFR1, KIT, PDGFRA, PDGFRB
15phosphatidylinositol-mediated signalingGO:00480159.0FGFR1, KIT, PDGFRA, PDGFRB
16positive regulation of phosphatidylinositol 3-kinase signalingGO:00140688.9FGFR1, KIT, PDGFRA, PDGFRB
17protein autophosphorylationGO:00467778.9FGFR1, KIT, PDGFRA, PDGFRB
18positive regulation of cell migrationGO:00303358.7KIT, PDGFRA, PDGFRB
19peptidyl-tyrosine phosphorylationGO:00181088.4FGFR1, IL5, KIT, PDGFRA, PDGFRB
20MAPK cascadeGO:00001658.2FGFR1, IL5, KIT, PDGFRA, PDGFRB
21positive regulation of GTPase activityGO:00435478.0FGFR1, IL5, KIT, PDGFRA, PDGFRB
22positive regulation of cell proliferationGO:00082848.0FGFR1, IL5, KIT, PDGFRA, PDGFRB

Molecular functions related to Hypereosinophilic Syndrome according to GeneCards Suite gene sharing:

(show all 7)
idNameGO IDScoreTop Affiliating Genes
1vascular endothelial growth factor bindingGO:003808510.1PDGFRA, PDGFRB
2platelet-derived growth factor receptor bindingGO:000516110.0PDGFRA, PDGFRB
3platelet-derived growth factor bindingGO:00484079.9PDGFRA, PDGFRB
4transmembrane receptor protein tyrosine kinase activityGO:00047149.4KIT, PDGFRA
5phosphatidylinositol-4,5-bisphosphate 3-kinase activityGO:00469348.8FGFR1, KIT, PDGFRA, PDGFRB
6protein tyrosine kinase activityGO:00047138.1FGFR1, IL5, KIT, PDGFRB
7Ras guanyl-nucleotide exchange factor activityGO:00050888.0FGFR1, IL5, KIT, PDGFRA, PDGFRB

Sources for Hypereosinophilic Syndrome

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
26GTR
27HGMD
28HMDB
29ICD10
30ICD10 via Orphanet
31ICD9CM
32IUPHAR
33KEGG
36MedGen
38MeSH
39MESH via Orphanet
40MGI
43NCI
44NCIt
45NDF-RT
48NINDS
49Novoseek
51OMIM
52OMIM via Orphanet
56PubMed
57QIAGEN
62SNOMED-CT via Orphanet
66Tumor Gene Family of Databases
67UMLS
68UMLS via Orphanet